BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Clinical News

Astellas' SGLT2 inhibitor meets Phase III endpoints in diabetes

Astellas Pharma Inc. (Tokyo:4503) said ipragliflozin met the primary endpoint in two Phase III trials to treat Type II diabetes. A Japanese trial in 151 patients with inadequate glycemic control on pioglitazone...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >